Single and Multiple Dose Study of MK-1942 in Healthy Japanese Adults

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1942 in Healthy Japanese Adult Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210214

Enrollment

Registered

2021-07-30

Start date

2021-08-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Treatment-Resistant Depression

Interventions

Single dose administration of MK-1942 (4, 8 or 10 mg) in the fasted state, single dose administration of MK-1942 (4 mg) in the fed state or multiple dose administration for 28 days of MK-1942 (8, 15,

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male aged 20 to 45 years old with BMI 18.5 to 25.0 kg/m2

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Part 1 (Single dose): -Adverse events, vital signs, laboratory safety tests, 12-lead electrocardiograms, physical examinations, neurological exams Part 2 (Multiple dose): -Adverse events, vital signs, laboratory safety tests, 12-lead electrocardiograms, physical examinations, neurological exams, Columbia suicide severity rating scale	—

Secondary

Measure	Time frame
Part 1 (Single dose): -AUC0-inf, Cmax, Tmax, apparent terminal t1/2, CL/F and Vz/F in the fasted state -AUC0-inf and Cmax in the fasted and fed state -AUC0-inf and Cmax in the fasted state between healthy Japanese participants with a CYP2C19 extensive metabolizer and poor metabolizer phenotype. Part 2 (Multiple dose): -Day 1: AUC0-12, Cmax, Tmax, Ctrough -Days 7, 14, 21 and 28: AUC0-12, Cmax, Tmax, Ctrough, apparent terminal t1/2, CL/F, Vz/F, accumulation ratios* * Following last dose only ** Day 7 only	—

Measure

Time frame

Part 1 (Single dose): -AUC0-inf, Cmax, Tmax, apparent terminal t1/2, CL/F and Vz/F in the fasted state -AUC0-inf and Cmax in the fasted and fed state -AUC0-inf and Cmax in the fasted state between healthy Japanese participants with a CYP2C19 extensive metabolizer and poor metabolizer phenotype. Part 2 (Multiple dose): -Day 1: AUC0-12, Cmax, Tmax, Ctrough -Days 7, 14, 21 and 28: AUC0-12, Cmax, Tmax, Ctrough, apparent terminal t1/2*, CL/F, Vz/F, accumulation ratios** * Following last dose only ** Day 7 only

—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026